ADXS News and Press, Advaxis From 04/28/21

PRINCETON, N.J., April 28, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS ), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that will present data from Part B of the Phase 1 study of ADXS-503 in co...

PRINCETON, N.J., April 26, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that the Company has achieved the second milestone under its licensing agr...

Advaxis (ADXS) has received the second milestone payment related to its licensing agreement for ADXS31-164, also known as ADXS-HER2, to OS Therapies for evaluation in the treatment of osteosarcoma in humans. Under the terms of the license agreement, OS Therapies is responsible for the conduct...

PRINCETON, N.J., April 26, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that the Company has received the second milestone payment related to its ...

Advaxis (ADXS) has entered into definitive agreements with two healthcare-focused, institutional investors for the purchase of shares and warrants, with a $20M registered direct offering priced at-the-market.The agreement is for the purchase of (i) 17.58M shares, (ii) 7.67M pre-fund...

PRINCETON, N.J., April 12, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced it has entered into definitive agreements wi...

Collaboration with Precision for Medicine to develop novel flow cytometry PD-1 expression assay as a pharmacodynamic biomarker in T cells during PD-1 blockade Assay enables determination of PD-1 expression independent of PD-1 receptor status, accounting for both free and drug-bo...

Advaxis (ADXS) announces an agreement with Columbia University Irving Medical Center to fund a Phase 1 clinical study evaluating ADXS-504 in patients with biochemically recurrent prostate cancer.The study, expected to begin in Q2, will evaluate the safety and tolerability of ADXS-504 monother...

PRINCETON, N.J., April 05, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced an agreement with Columbia University Irving Medical Center to fund a Phase 1 ...

Cheap Penny Stocks On Robinhood Are Hard To Come By Buying penny stocks on Robinhood has become the norm for many traders. Given the app’s easy set-up and clear-cut operating platform, millions of new retail traders have made it their go-to platform. I know there’ve be...